TMEM131L

Across TCGA pan-cancer cohorts, TMEM131L Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TMEM131L data layer compared with 27 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TMEM131L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM131L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, BRCA, and UCEC are the cancer types where TMEM131L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.082	0.702	<.001	24	view →
BRCA	OS	Median	III,IV	0.553	0.906	<.001	24	view →
UCEC	DFS	Median	All	0.810	0.623	.008	16	view →
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
LUAD	DFS	Median	III,IV	0.036	0.673	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SARC	DFS	Median	All	0.098	0.591	.010	3	view →
READ	DFS	Median	III,IV	0.182	0.746	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TMEM131L–SCLC (OS)

Open the SCLC breakdown →